Progress in cancer therapy targeting c-Met signaling pathway
暂无分享,去创建一个
[1] E. Gherardi,et al. Hepatocytes and scatter factor , 1990, Nature.
[2] L. Naldini,et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. , 2004, Cancer cell.
[3] J. Christensen,et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. , 2003, Cancer research.
[4] G. Merlino,et al. Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1 , 2002, Oncogene.
[5] L. Naldini,et al. An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. , 2004, The Journal of clinical investigation.
[6] N. Senzer,et al. A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors , 2011, Clinical Cancer Research.
[7] P. Scherle,et al. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. , 2010, Trends in molecular medicine.
[8] Joon-Oh Park,et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.
[9] S. Jeay,et al. ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity , 2010, Molecular Cancer Therapeutics.
[10] P. Circosta,et al. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[11] K. Yamaguchi,et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. , 2009, Cancer research.
[12] G. Woude,et al. Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis , 2004, Oncogene.
[13] Shinji Yamazaki,et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. , 2007, Cancer research.
[14] M. Stella,et al. Negative Feedback Regulation of Met-Dependent Invasive Growth by Notch , 2005, Molecular and Cellular Biology.
[15] A. Bardelli,et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway , 1998, Nature.
[16] Gayatry Mohapatra,et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[17] J. Christensen,et al. Expression and mutational analysis of MET in human solid cancers , 2008, Genes, chromosomes & cancer.
[18] J. Schlessinger,et al. Activation of the JNK pathway is essential for transformation by the Met oncogene , 1997, The EMBO journal.
[19] D. Collins,et al. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] W. Ma,et al. Novel Agents on the Horizon for Cancer Therapy , 2009, CA: a cancer journal for clinicians.
[21] Stephen K Burley,et al. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo , 2009, Molecular Cancer Therapeutics.
[22] J. Laterra,et al. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] E. Medico,et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. , 2011, Journal of the National Cancer Institute.
[24] W. Birchmeier,et al. Evidence for the identy of human scatter factor and human hepatocyte growth factor. , 1991 .
[25] M. Stella,et al. Cross-talk between the proto-oncogenes Met and Ron , 2000, Oncogene.
[26] W. Birchmeier,et al. Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.
[27] L. Trusolino,et al. MET signalling: principles and functions in development, organ regeneration and cancer , 2010, Nature Reviews Molecular Cell Biology.
[28] W. Birchmeier,et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[29] M. Karamouzis,et al. Trastuzumab--mechanism of action and use. , 2007, The New England journal of medicine.
[30] Jilin Sun,et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. , 2006, Cancer research.
[31] Laura A. Sullivan,et al. Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.
[32] A. Ullrich,et al. Reactive Oxygen Species Mediate Met Receptor Transactivation by G Protein-coupled Receptors and the Epidermal Growth Factor Receptor in Human Carcinoma Cells* , 2004, Journal of Biological Chemistry.
[33] R. Jove,et al. Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis , 2002, Oncogene.
[34] William Pao,et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.
[35] G. V. Vande Woude,et al. Showering c-MET-dependent cancers with drugs. , 2008, Current opinion in genetics & development.
[36] J. Stamos,et al. The Sema domain of Met is necessary for receptor dimerization and activation. , 2004, Cancer cell.
[37] A. Bardelli,et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family , 1994, Cell.
[38] J. Sarkaria,et al. An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth. , 2010, Anti-cancer agents in medicinal chemistry.
[39] J. Rubin,et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. , 1991, Science.
[40] D. Kamikura,et al. A switch from p130Cas/Crk to Gab1/Crk signaling correlates with anchorage independent growth and JNK activation in cells transformed by the Met receptor oncoprotein , 2000, Oncogene.
[41] G. Kovacs,et al. Molecular cytogenetics of renal cell tumors. , 1993, Advances in cancer research.
[42] P. Scherle,et al. Targeting the c-MET signaling pathway for cancer therapy , 2008 .
[43] L. Trusolino,et al. Drug development of MET inhibitors: targeting oncogene addiction and expedience , 2008, Nature Reviews Drug Discovery.
[44] A. Bardelli,et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. , 1991, The EMBO journal.
[45] W. Muller,et al. HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. , 2004, Molecular biology of the cell.
[46] A. Bardelli,et al. The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. , 1995, Oncogene.
[47] K. Rex,et al. AMG 102, A Fully Human Anti-Hepatocyte Growth Factor/Scatter Factor Neutralizing Antibody, Enhances the Efficacy of Temozolomide or Docetaxel in U-87 MG Cells and Xenografts , 2007, Clinical Cancer Research.
[48] Toshikazu Nakamura,et al. Mechanisms and significance of bifunctional NK4 in cancer treatment. , 2005, Biochemical and biophysical research communications.
[49] C. Birchmeier,et al. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. , 1998, Trends in cell biology.
[50] G. Shapiro,et al. A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2 , 2010, Clinical Cancer Research.
[51] C. Birchmeier,et al. Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development , 1993, The Journal of cell biology.
[52] E. Birney,et al. Patterns of somatic mutation in human cancer genomes , 2007, Nature.
[53] J. Christensen,et al. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. , 2005, Cancer letters.
[54] M. Westphal,et al. A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo , 2006, Clinical Cancer Research.
[55] E Medico,et al. Expression of the Met/HGF receptor in normal and neoplastic human tissues. , 1991, Oncogene.
[56] W. Marston Linehan,et al. Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas , 1998, Nature Genetics.